Latest period
$3.36B
YoY change
+22.9%
5Y CAGR
+24.9%
Peak year (2025)
$14.57B
Latest annual
$14.57B
Operating Cash Flow history chart for AstraZeneca (AZN) from 1990 to 2025
Latest: $14.57B
Operating Cash Flow growth chart for AstraZeneca (AZN) from 1990 to 2025
Latest: +22.9%
Operating Cash Flow history table for AstraZeneca (AZN) from 1990 to 2025
| 2025 | $14.57B | +22.9% | +$2.71B | ||
| 2024 | $11.86B | +14.7% | +$1.52B | ||
| 2023 | $10.35B | +5.5% | +$537.00M | ||
| 2022 | $9.81B | +64.5% | +$3.85B | ||
| 2021 | $5.96B | +24.3% | +$1.16B | ||
| 2020 | $4.80B | +61.6% | +$1.83B | ||
| 2019 | $2.97B | +13.4% | +$351.00M | ||
| 2018 | $2.62B | -26.8% | −$960.00M | ||
| 2017 | $3.58B | -13.7% | −$567.00M | ||
| 2016 | $4.14B | +24.7% | +$821.00M | ||
| 2015 | $3.32B | -52.9% | −$3.73B | ||
| 2014 | $7.06B | -4.6% | −$342.00M | ||
| 2013 | $7.40B | +6.5% | +$452.00M | ||
| 2012 | $6.95B | -11.2% | −$873.00M | ||
| 2011 | $7.82B | -26.8% | −$2.86B | ||
| 2010 | $10.68B | -9.0% | −$1.06B | ||
| 2009 | $11.74B | +34.3% | +$3.00B | ||
| 2008 | $8.74B | +16.4% | +$1.23B | ||
| 2007 | $7.51B | -2.4% | −$183.00M | ||
| 2006 | $7.69B | +14.1% | +$950.00M | ||
| 2005 | $6.74B | +38.4% | +$1.87B | ||
| 2004 | $4.87B | +42.7% | +$1.46B | ||
| 2003 | $3.42B | -29.3% | −$1.42B | ||
| 2002 | $4.83B | +78.6% | +$2.13B | ||
| 2001 | $2.71B | +15.9% | +$370.51M | ||
| 2000 | $2.34B | +157.1% | +$1.43B | ||
| 1999 | $908.55M | +3.3% | +$28.81M | ||
| 1998 | $879.74M | +17.7% | +$132.53M | ||
| 1997 | $747.21M | -5.1% | −$40.55M | ||
| 1996 | $787.75M | +34.5% | +$202.12M | ||
| 1995 | $585.64M | -6.4% | −$39.73M | ||
| 1994 | $625.36M | -11.4% | −$80.22M | ||
| 1993 | $705.58M | +242.1% | +$499.31M | ||
| 1992 | $206.27M | -59.2% | −$298.95M | ||
| 1991 | $505.22M | -37.3% | −$301.08M | ||
| 1990 | $806.30M | — | — |
- 2025$14.57B+22.9%
- 2024$11.86B+14.7%
- 2023$10.35B+5.5%
- 2022$9.81B+64.5%
- 2021$5.96B+24.3%
- 2020$4.80B+61.6%
- 2019$2.97B+13.4%
- 2018$2.62B-26.8%
- 2017$3.58B-13.7%
- 2016$4.14B+24.7%
- 2015$3.32B-52.9%
- 2014$7.06B-4.6%
- 2013$7.40B+6.5%
- 2012$6.95B-11.2%
- 2011$7.82B-26.8%
- 2010$10.68B-9.0%
- 2009$11.74B+34.3%
- 2008$8.74B+16.4%
- 2007$7.51B-2.4%
- 2006$7.69B+14.1%
- 2005$6.74B+38.4%
- 2004$4.87B+42.7%
- 2003$3.42B-29.3%
- 2002$4.83B+78.6%
- 2001$2.71B+15.9%
- 2000$2.34B+157.1%
- 1999$908.55M+3.3%
- 1998$879.74M+17.7%
- 1997$747.21M-5.1%
- 1996$787.75M+34.5%
- 1995$585.64M-6.4%
- 1994$625.36M-11.4%
- 1993$705.58M+242.1%
- 1992$206.27M-59.2%
- 1991$505.22M-37.3%
- 1990$806.30M—
Operating Cash Flow values are taken from AstraZeneca's reported cash flow statements (interim 6-K and annual 20-F filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Operating Cash Flow at AstraZeneca (AZN)
Operating Cash Flow for AstraZeneca (AZN): headline value $3.36B · YoY +22.9%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
AstraZeneca (AZN) most recent annual operating cash flow stands at $14.57B (2025) – grew 22.9% year-over-year.
AstraZeneca operating cash flow compound annual growth for the 2020–2025 (5 years) window is +24.9%, sustaining 7 straight years of year-over-year growth.
Across the available history, operating cash flow reached its high of $14.57B in 2025 and its low of $206.27M in 1992.
AstraZeneca Operating Cash Flow by Year
AstraZeneca Operating Cash Flow 2025: $14.57B
AstraZeneca operating cash flow in 2025 was $14.57B, grew 22.9% from 2024. This figure represents the highest annual value in the available history.
AstraZeneca Operating Cash Flow 2024: $11.86B
2024's operating cash flow for AstraZeneca came in at $11.86B, grew 14.7% from 2023.
AstraZeneca Operating Cash Flow 2023: $10.35B
AstraZeneca posted operating cash flow of $10.35B in 2023, grew 5.5% from 2022.
AstraZeneca Operating Cash Flow 2022: $9.81B
In 2022, AstraZeneca reported operating cash flow of $9.81B, surged 64.5% from 2021.
AstraZeneca Operating Cash Flow 2021: $5.96B
AstraZeneca operating cash flow in 2021 was $5.96B.
See more financial history for AstraZeneca (AZN).
Sector peers by Operating Cash Flow
Healthcare peers of AstraZeneca (AZN), ranked by their latest operating cash flow
| $24.53B | |
| $19.70B | |
| $19.03B | |
| $18.56B | |
| $16.81B | |
| $16.47B | |
| $9.96B | |
| $7.82B |
- $24.53B
- $19.70B
- $19.03B
- $18.56B
- $16.81B
- $16.47B
- $9.96B
Frequently asked questions
AstraZeneca (AZN) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation